SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ: CYTX) received two Notices of Allowance from the U.S. Patent & Trademark Office for patents, which cover methods related to the Celution® System output. These patent allowances add specific commercial applications to U.S. Patent No. 7,390,484, issued in June 2008, which covers the Celution System technology that processes adipose-derived stem and regenerative cells at a patient’s bedside. The new patent allowances will provide significant additional protection for wide-ranging formulations and applications of the Celution System output.
